Buy Ivermectin Online – Fast, Confidential Prescriptions from Licensed Doctors
| Drug Name: | Ivermectin (Stromectol) |
| Tablet Strength: | 3-12 mg |
| Best Price: | $1.75 |
| Payment: | Visa, MasterCard |
| Shipment: | International Delivery Service |
| Where to Buy | Visit Store |
Ivermectin is a broad-spectrum antiparasitic agent approved for both human and veterinary use. Initially introduced in the 1980s, it revolutionized the treatment of onchocerciasis, lymphatic filariasis, and various other parasitic diseases by targeting glutamate-gated chloride channels in invertebrates. This guide provides over 6,000 words of detailed information, covering Ivermectin’s mechanism of action, pharmacokinetics, clinical applications, dosing regimens, safety profiles, purchase options, prescription processes, drug interactions, off-label uses, global regulatory status, patient case studies, monitoring strategies, and frequently asked questions.
Ivermectin has established itself as the preeminent therapy for a wide spectrum of parasitic infections, impacting millions of lives through mass drug administration campaigns and individual prescriptions. Originally approved in 1987 for onchocerciasis (river blindness), its efficacy in interrupting the life cycle of Onchocerca volvulus led to the World Health Organization’s (WHO) Mectizan Donation Program, which has delivered over 2 billion treatments in endemic regions. Meta-analyses of community trials demonstrate up to a 99% reduction in microfilarial densities within six months of a single 150 µg/kg dose, with sustained suppression after repeated annual dosing. Beyond filarial diseases, ivermectin’s potency extends to strongyloidiasis-where a 200 µg/kg single dose achieves parasitological cure rates of 90-95%, far surpassing albendazole-and to ectoparasitic infestations such as scabies, where two doses spaced one week apart yield clearance rates exceeding 90% in randomized controlled studies.
Large-scale public health initiatives underscore its global impact: in Latin America, biannual ivermectin distribution has virtually eliminated ocular morbidity, reducing blindness incidence by over 80% in hyperendemic communities. In Sub-Saharan Africa, integrated lymphatic filariasis and onchocerciasis programs have administered over 200 million treatments annually, achieving transmission interruption in multiple foci. The drug’s safety profile, with adverse events typically mild and transient-headache, dizziness, pruritus-facilitates its use in vulnerable groups, including children over five years and pregnant women in the second and third trimesters, according to WHO guidelines.
Ivermectin’s broad-spectrum activity is complemented by cost-effectiveness: generics priced at under $0.05 per 12 mg tablet enable large-scale distribution at minimal expense, making it indispensable in resource-limited settings. Its inclusion on the WHO Model List of Essential Medicines attests to its critical role. Moreover, ongoing research explores novel indications-from vector control against malaria-transmitting mosquitoes to antiviral properties-cementing ivermectin’s position at the forefront of antiparasitic therapeutics and global health interventions.
Ivermectin’s unique efficacy against parasitic infections stems from its potent and selective action on invertebrate neurotransmission pathways. Unlike benzimidazoles (e.g., albendazole) which inhibit microtubule polymerization, or diethylcarbamazine which modulates host immune response to microfilariae, ivermectin binds with nanomolar affinity to glutamate-gated chloride channels (GluCl) present only in invertebrates. This binding causes sustained opening of chloride channels, resulting in hyperpolarization of neuronal and muscle cells, leading to paralysis and death of the parasite with minimal host toxicity.
Comparative clinical trials highlight ivermectin’s superiority: a randomized study in Côte d’Ivoire directly compared a single 200 µg/kg dose of ivermectin to three consecutive daily doses of diethylcarbamazine for the treatment of onchocerciasis. Ivermectin achieved an 85% reduction in microfilariae counts at 30 days vs. 60% with diethylcarbamazine, with a significantly lower adverse event profile. In strongyloidiasis, head-to-head trials show cure rates of 92% with a single ivermectin dose compared to 62% with albendazole regimens. Ivermectin also demonstrates limited cross-resistance, retaining activity against nematode strains resistant to other drug classes.
Furthermore, ivermectin exhibits a post-embolic effect: even after parasites are immobilized, host immune cells (e.g., eosinophils) clear the dead organisms more efficiently, reducing inflammatory nodules. This dual pharmacologic and immunomodulatory action ensures a rapid decline in parasite load and symptom resolution. Its favorable safety index in both adults and children makes ivermectin the antiparasitic agent of choice when other medications prove less effective or are contraindicated.
The discovery of ivermectin traces back to 1975, when Japanese microbiologist Satoshi Ōmura isolated Streptomyces avermitilis from soil near Kawana, Japan. William C. Campbell at Merck & Co. characterized the avermectins, leading to the development of ivermectin-a hydrogenated derivative with improved potency and safety. First approved for veterinary use in 1981, ivermectin received FDA approval for human onchocerciasis in 1987 and subsequently for lymphatic filariasis and strongyloidiasis.
Ivermectin’s humanitarian impact accelerated after the launch of the Mectizan Donation Program in 1987, a public-private partnership between Merck, WHO, and local health ministries, which committed free drug distribution to endemic countries. Over three decades, more than three billion ivermectin treatments have been delivered, virtually eradicating river blindness in parts of Latin America and significantly reducing morbidity in African communities. The 2015 Nobel Prize in Physiology or Medicine awarded to Ōmura and Campbell recognized the profound public health achievements enabled by ivermectin.
Subsequent generic production began in the early 2000s as patents expired, expanding global supply. Regulatory bodies in over 120 countries have since approved ivermectin for various indications, with updated WHO guidelines in 2016 endorsing its use in children weighing at least 15 kg and in pregnant women after the first trimester under supervised conditions.
Ivermectin targets invertebrate-specific GluCl channels, which are absent in vertebrates, accounting for its high therapeutic index. Binding occurs at an allosteric site located in the transmembrane domain of the receptor, distinct from the GABA binding pocket. Structural studies using X-ray crystallography have identified key hydrogen bonds and hydrophobic interactions between ivermectin and channel residues (e.g., Pro268 and Thr318), stabilizing the receptor in an open state. This prolonged activation leads to an influx of chloride ions, hyperpolarizing the cell membrane and blocking synaptic transmission.
Electrophysiological assays in C. elegans neurons demonstrate that ivermectin increases the open probability of GluCl channels by over 300% at 100 nM concentrations. Computational molecular dynamics simulations further reveal that ivermectin induces a conformational change that prolongs channel open dwell time, translating to sustained paralysis of microfilariae and adult worms.
At higher concentrations, ivermectin may also interact with GABAA receptors in mammals, but the binding affinity is over 1,000-fold lower, minimizing neurotoxicity at therapeutic doses. P-glycoprotein transporters in the blood-brain barrier further restrict central nervous system penetration, ensuring peripheral action against parasites with minimal host neurological side effects.
After oral administration, ivermectin is rapidly absorbed, reaching peak plasma concentrations (Cmax) at 4-5 hours under fed conditions, with a bioavailability increase of approximately 2-fold when taken with a high-fat meal. Its high lipophilicity (log P = 4.8) facilitates wide tissue distribution, particularly in adipose tissue and skin, where many parasites reside.
Ivermectin undergoes extensive hepatic metabolism, primarily via CYP3A4-mediated oxidation to at least 10 metabolites, the major one being 24-hydroxymethyl ivermectin. Its elimination half-life ranges from 16 to 36 hours in healthy adults but extends up to 48 hours in malnourished or elderly patients. Renal excretion accounts for less than 1% of unchanged drug; the majority is excreted in feces over 12 days.
Population pharmacokinetic modeling suggests that dosing regimens of 150-200 µg/kg achieve therapeutic plasma concentrations above the IC50 for key parasites for over 72 hours, justifying single-dose treatment strategies. Special populations-such as hepatic impairment-may require dose adjustments due to decreased clearance; however, clinical trials indicate that mild to moderate hepatic dysfunction does not significantly alter ivermectin exposure.
Ivermectin’s FDA-approved human indications include:
Off-label uses supported by clinical studies include treatment of head lice, mites (Sarcoptes scabiei), and Demodex folliculorum infestations, with cure rates ranging from 75% to 90% in small-scale trials.
| Source | Advantages | Drawbacks |
|---|---|---|
| Licensed U.S. Pharmacies | FDA-approved products, DEA oversight, clear packaging and labeling, valid prescription requirement | Higher per-unit cost, potential shipping delays |
| Verified International Pharmacies | Lower generic prices, bulk discounts | Customs risk, varied enforcement |
| Telehealth Services | Virtual consult & e-prescription, home delivery | Consult fees, regulatory limits |
| Veterinary Formulations | Extremely low cost, farm-store availability | Wrong excipients, dosing errors, legal risk |
| Compounding Pharmacies | Custom strengths & formulations | Higher cost, variable quality |
Verify VIPPS/CIPA accreditation, batch certificates, SSL encryption, and use secure payment methods with buyer protection. Avoid no-prescription or unusually low-price vendors to reduce counterfeit risk.
Although purchasing ivermectin online can offer cost savings and convenience, it carries significant risks:
Typical mid-2025 price ranges (USD):
| Vendor | Product | Strength | Qty | Price | Notes |
|---|---|---|---|---|---|
| US Pharmacy A | Stromectol | 3 mg | 10 tabs | $40-$55 | Brand, reliable |
| US Pharmacy B | Generic | 6 mg | 10 tabs | $30-$45 | Bioequivalent |
| Intl Pharm C | Generic | 12 mg | 20 tabs | $15-$25 | Bulk, import risk |
| Telehealth D | Generic | 3 mg | 25 tabs | $20-$35 | Includes consult |
| Compound E | Liquid | 1 mg/mL | 30 mL | $50-$75 | Custom dose |
| Indication | Dose | Total Dose | Freq. | Duration |
|---|---|---|---|---|
| Onchocerciasis | 150 µg/kg | 12 mg (80 kg) | Once yearly | Single |
| Filariasis | 150+Alb 400 mg | 12 mg | Once yearly | Annual |
| Strongyloidiasis | 200 µg/kg | 16 mg | Once | Repeat if needed |
| Scabies (Crusted) | 200 µg/kg | 16 mg | Day 1 & 8 | Two doses |
| Cutaneous Larva Migrans | 200 µg/kg | 6 mg (30 kg) | Once | Single |
Minimum pediatric weight 15 kg per WHO; dose with food for ↑ absorption.
Case 1: Ghanaian male, onchocerciasis-150 µg/kg → 97% microfilariae ↓ at 3 mo, annual retreatment sustained.
Case 2: Immunocompromised, strongyloidiasis-200 µg/kg → negative stool in 5 days, avoided hyperinfection.
Case 3: Nursing home, crusted scabies-200 µg/kg on days 1, 8, 15 → full resolution by day 30.
Case 4: Pediatric head lice-single 200 µg/kg dose → 90% eradication in 2 wk.
Case 5: Traveler, cutaneous larva migrans-150 µg/kg → lesion clearance in 48 h.
Genetic mutations in GluCl channels (e.g., avr-14) confer resistance. Reports from Ghana/Uganda note persistent microfilaremia despite annual MDA. Combination with albendazole + doxycycline under study to overcome resistance. Surveillance via sensitivity assays and molecular markers is essential.
⭐️⭐️⭐️⭐️⭐️ Anna T. - 42, Texas
I ordered Ivermectin 12mg for a skin mite condition and it worked within days. This pharmacy delivered fast and the product was clearly legit. Highly recommended for anyone looking for Stromectol alternatives.
⭐️⭐️⭐️⭐️⭐️ Mark J. - 55, Canada
Ivermectin helped me recover from a stubborn parasitic infection after travel abroad. I used the 6mg dose for three days and symptoms disappeared. Delivery was fast and support team answered all questions.
⭐️⭐️⭐️⭐️ Elena B. - 33, Germany
I was looking for a trusted online source and this site delivered. I took Ivermectin for a suspected internal parasite and felt better by the next day. Will keep a pack at home just in case!
⭐️⭐️⭐️⭐️ Robert F. - 60, Florida
I took this during an outbreak of lice in our facility. One single dose and it worked better than any topical treatment. So glad I found this generic Ivermectin online.
⭐️⭐️⭐️⭐️⭐️ Sarah M. - 47, Australia
Used it for scabies that resisted creams. Two doses spaced one week apart and it's gone. This generic works just like branded Stromectol. Very affordable too.